https://www.selleckchem.com/products/osmi-4.html
7 (-14.2 - -7. %/yr vs 2.0 (-7.1 - 6. %/yr; n=17; p0.01). In the slow decliners, pirfenidone did not reduce the median (IQR) annual rate of decline in FVC % predicted (-1.3 (-3.2 - 1.3) %/yr vs -5.0 (-8.3 - -0.35) %/yr; n=17; p=0.028). We demonstrate the greater net effect of pirfenidone in IPF patients declining rapidly. We suggest that using an annual rate of decline in FVC of 5% and ≥5% may be useful in counselling patients with regard to pirfenidone treatment. . We demonstrate the greater net effect of pirfenidone in IPF
Like
Comment
Share
